Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 2g. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories, and Non-U.S. Residents, 2021†
Reporting Area Giardiasis Gonorrhea Haemophilus influenzae, invasive disease Hansen's disease
All ages, all serotypes Age <5 years
Serotype b Non-b serotype Nontypeable Unknown serotype
U.S. Residents, excluding U.S. Territories 11,643 699,585 3,042 27 137 94 172 57
New England 836 16,537 120 — 1 3 — —
Connecticut 150 5,405 17 — 1 — — —
Maine 140 462 14 — — 1 — N
Massachusetts 383 8,240 60 — — 2 — —
New Hampshire 108 613 8 — — — — —
Rhode Island 55 1,681 15 — — — — —
Vermont N 136 6 — — — — N
Middle Atlantic 2,591 72,219 362 7 11 7 15 2
New Jersey 307 10,259 66 — — — 6 —
New York (excluding New York City) 968 14,919 87 2 6 2 3 N
New York City 810 28,129 52 1 2 — — 1
Pennsylvania 506 18,912 157 4 3 5 6 1
East North Central 1,426 105,183 615 8 33 17 12 3
Illinois N 30,454 112 — 5 3 2 —
Indiana 133 14,483 112 3 7 5 2 1
Michigan 433 21,954 156 1 4 3 4 1
Ohio 295 27,838 156 3 14 6 2 —
Wisconsin 565 10,454 79 1 3 — 2 1
West North Central 1,084 45,479 236 2 5 — 37 4
Iowa 172 6,403 2 — — — 2 —
Kansas 121 5,646 36 — — — 6 —
Minnesota 387 9,660 56 — — — 14 1
Missouri 193 15,714 93 — — — 8 2
Nebraska 92 3,063 23 1 — — 5 —
North Dakota 48 1,735 9 — 1 — 2 N
South Dakota 71 3,258 17 1 4 — — 1
South Atlantic 1,631 143,223 731 2 17 15 43 14
Delaware 36 1,541 7 — — — 2 1
District of Columbia 5 4,322 — — — — — —
Florida 710 44,738 226 2 5 5 17 13
Georgia 248 31,996 172 — 5 — 10 —
Maryland 123 U 56 — — 2 1 —
North Carolina N 28,612 113 — 4 8 1 —
South Carolina 138 16,052 65 — — — 10 —
Virginia 283 14,323 67 — 1 — 1 —
West Virginia 88 1,639 25 — 2 — 1 N
East South Central 279 55,756 212 1 15 5 29 7
Alabama 162 16,189 85 — 4 4 17 —
Kentucky 117 8,182 35 — 4 1 4 1
Mississippi N 12,617 23 — 3 — 2 5
Tennessee N 18,768 69 1 4 — 6 1
West South Central 393 99,462 449 — 30 27 20 15
Arkansas 151 8,176 50 — 4 3 1 —
Louisiana 242 16,390 85 — 3 1 9 1
Oklahoma N 10,273 85 — 7 5 — N
Texas N 64,623 229 — 16 18 10 14
Mountain 1,115 49,379 236 3 6 12 13 2
Arizona 91 18,426 69 1 1 7 1 —
Colorado 481 10,596 43 — 1 2 — —
Idaho 132 1,197 25 1 1 2 1 —
Montana 60 1,448 16 — 1 — — —
Nevada 69 8,488 22 1 — 1 2 —
New Mexico 31 5,080 21 — 2 — — —
Utah 216 3,621 37 — — — 9 2
Wyoming 35 523 3 — — — — —
Pacific 2,288 112,347 81 4 19 8 3 10
Alaska 63 1,977 15 — 5 — 1 —
California 1,606 91,461 17 1 8 6 2 3
Hawaii 42 1,457 11 — — — — 7
Oregon 340 6,221 31 2 1 1 — N
Washington 237 11,231 7 1 5 1 — N
U.S. Territories 21 1,316 — — — — — 15
American Samoa — 11 — — — — — —
Commonwealth of Northern Mariana Islands — 17 — — — — — —
Guam — 198 — — — — — 15
Puerto Rico 21 1,012 — — — — — —
U.S. Virgin Islands — 78 — — — — — —
Non-U.S. Residents 3 42 — — — — — —
Total 11,667 700,943 3,042 27 137 94 172 72
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
  • U: Unavailable — The data are unavailable.
  • * Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see https://www.cdc.gov/nndss/data-statistics/readers-guides/.
  • † To calculate rates, use the populations provided in Table 8. Note that calculation of rates for the following conditions uses population subgroups as described in note #7 and population counts presented in Table 8: Zika virus infection, congenital; Zika virus disease, congenital; Infant botulism; Congenital rubella syndrome; Perinatal Hepatitis B infection; Perinatal Hepatitis C infection; Haemophilus influenzae, invasive disease; Invasive pneumococcal disease; and Influenza-associated pediatric mortality. Also see Notes #3 and #7.
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2021 annual tables were officially closed on March 29, 2023.
  2. The list of national notifiable Infectious diseases and conditions for 2021 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2021" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". CSTE adopted the first coronavirus disease 2019 (COVID-19) national surveillance case definition on April 5, 2020, and they approved a revision to the COVID-19 national surveillance case definition, effective August 5, 2020. On June 17, 2021, a revision to the COVID-19 national surveillance case definition was approved, effective September 1, 2021. Publication criteria for the finalized 2021 data are available at https://wonder.cdc.gov/nndss/documents/2021_NNDSS_Publication_Criteria_03162022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2020, estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010, to July 1, 2020, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2020), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released September 22, 2021, are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2020 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on March 15, 2022, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks, select "Annual Reports" in the "Genre" box to the left).
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction in numerator and denominator is ≤24 months)
    • Perinatal hepatitis C infection (age restriction in numerator and denominator is ≤36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2021 (National Center for Health Statistics Natality 2021, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. Disease data presented in the 2021 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.